Clinical Scorecard: This Week’s CGT News: Base Editing Takes Aim at Cholesterol
At a Glance
| Category | Detail |
|---|---|
| Condition | Heterozygous familial hypercholesterolemia or premature coronary artery disease |
| Key Mechanisms | Inactivation of PCSK9 in the liver using adenine base editing |
| Target Population | Adults with heterozygous familial hypercholesterolemia or premature coronary artery disease |
| Care Setting | Phase 1 clinical trial |
Key Highlights
- VERVE-102 showed up to 88% reduction in PCSK9 and 62% reduction in LDL-C
- No dose-limiting toxicities reported in the study
- Mild-to-moderate infusion reactions and transient liver enzyme elevations observed
- Effects appeared durable through follow-up of at least one year in 15 participants
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Mild-to-moderate infusion reactions
- Transient liver enzyme elevations
Patient & Prescribing Data
35 participants in an open-label, single-ascending-dose study
One-time treatment delivered via lipid nanoparticle
Clinical Best Practices
- Monitor liver enzyme levels post-treatment
- Assess for infusion reactions during administration
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
